Prevention of Heart Disease

  • Ross Lorimer

Abstract

The prevention of heart disease in Britain received little attention in the first part of the century because of the scourge of infectious diseases. Treatment was essentially symptomatic since accurate diagnosis and the classification of disease entities were in their infancy. In the United States, by contrast, the leading American cardiologist Paul Dudley White wrote a paper in 1922 entitled “The diagnosis of heart disease, with especial reference to its importance in prevention”.[1] In the 1951 edition of his textbook, Heart disease, White wrote, “By the early 1920s, the present day fundamental classification of cardiac diagnosis based primarily on aetiology had been well established. The major importance of this step was indicated not only by better diagnosis and treatment but especially by the directing of attention to the causes of heart disease, the elucidation of which will undoubtedly lead to effective preventive medicine, so much more important in the final analysis than research, interesting though it is, in abnormal physiology, and in therapy, both medical and surgical.”[2] A review of White’s work, published in 1973, included the statement “preventive medicine is the aim of every clear thinking physician who has the welfare of the race in his mind.”[3]

Keywords

Cholesterol Smoke Propranolol Triglyceride Fibrinogen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and notes

  1. 1.
    White PD. The diagnosis of heart disease, with especial reference to its importance in preventive medicine. Boston Med Surg J, 1922;186:34–8.Google Scholar
  2. 2.
    White PD. Heart disease. 4th ed. New York: McMillan Co, 1951.Google Scholar
  3. 3.
    White PD. The early infancy of preventive cardiology. Am Clin Climatol Soc 1973;84:17–21.Google Scholar
  4. 4.
    Davidson LSP. Diseases of the cardiovascular system. In:Principles and practice of medicine. 3rd ed. Edinburgh, Livingston, 1956:57.Google Scholar
  5. 5.
    Bywaters EGL, Thomas GT. Prevention of rheumatic fever recurrences. BMJ 1958;2:350.PubMedCrossRefGoogle Scholar
  6. 6.
    Perry CB, Gillespie WA. Intramuscular benzathine penicillin in the prophylaxis of streptococcal infection in rheumatic children. BMJ 1954;1:729–30.CrossRefGoogle Scholar
  7. 7.
    Rheumatic Fever Committee of the Royal College of Physicians. Further report. London: Royal College of Physicians, 1957.Google Scholar
  8. 8.
    Bywaters EGL, Thomas GT. Treatment and prevention of rheumatic fever. In: Jones AM, ed. Modern trends in cardiology. London: Butterworths, 1961:100–114.Google Scholar
  9. 9.
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1383–89.Google Scholar
  11. 11.
    McNee JW. The clinical syndrome of thrombosis of the coronary arteries. Q J Med;44:1925.Google Scholar
  12. 12.
    McCormick J. James Mackenzie lecture. Fifty years of progress. Practitioner 1975;214:87–97.PubMedGoogle Scholar
  13. 13.
    MacKenzie J. Angina pectoris. Oxford: Medical Publications, 1923.Google Scholar
  14. 14.
    Doll R, Hill AB. The mortality of doctors in relation to their smoking habits. BMJ 1954;1451–7.Google Scholar
  15. 15.
    Morris JN. Aetiology of ischaemic heart disease. Proc R Soc Med 1962;33:693–5.Google Scholar
  16. 16.
    Morris JN, Heady JA, Raffle PAB, Roberts CG, Parks JW. Coronary heart disease and physical activity at work. Lancet 1953;264:1053–7.CrossRefGoogle Scholar
  17. 17.
    Morris JN, Heady JA, Raffle PAB, Roberts CG, Parks JW. Coronary heart disease and physical activity at work. Lancet 1953;264:1111–20.CrossRefGoogle Scholar
  18. 18.
    Bronte-Stewart B. The effects of dietary fats on the blood lipids. Br Med Bull 1958;14:243–51.PubMedGoogle Scholar
  19. 19.
    Oliver MF. Ischaemic heart disease. An assessment of the value of reducing raised plasma lipids. Lancet 1962;i:653–6.CrossRefGoogle Scholar
  20. 20.
    Oliver MF. The significance of elevated plasma lipids in relation to the prevention of ischaemic heart disease. Bull WHO 1962;27:409–19.PubMedGoogle Scholar
  21. 21.
    Oliver MF. Current therapeutics CXCV. Atromid S and Atromid. Practitioner 1964;192:424.PubMedGoogle Scholar
  22. 22.
    A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069–1118.CrossRefGoogle Scholar
  23. 24.
    Rose G, Hamilton PS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart disease. Lancet 1977;i:105–9.Google Scholar
  24. 25.
    Rose GA, Shipley M. Plasma cholesterol concentrations and death from coronary heart disease. BMJ 1986;293:306–7.PubMedCrossRefGoogle Scholar
  25. 26.
    Morris JN, Crawford M, Heady JA. Hardness of local water supplies and mortality. From Cardiovascular Disease. Lancet 1961;i:860.Google Scholar
  26. 27.
    Pocock SJ, Shaper AG, Cook PG, Lacey RF, Powell P, Russell PF. British regional heart study: graphic variations in cardiovascular mortality and the role of water quality. BMJ 1980;280:1243–9.PubMedCrossRefGoogle Scholar
  27. 28.
    Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British regional heart study: cardiovascular risk factors in middle aged men in 24 towns. BMJ 1981;283:179–86.PubMedCrossRefGoogle Scholar
  28. 29.
    Price FW, ed. A text book of the practice of medicine. 6th ed. London: Oxford University Press, 1941:981.Google Scholar
  29. 30.
    Rose G, Marmot M. Social class and coronary heart disease. BMJ 1981;45:13–19.Google Scholar
  30. 31.
    Shaper AG, Cook DG, Walker M, MacFarlane PW. Prevalence of heart disease in middle aged British men. Br Heart J 1984;51:595–605.PubMedCrossRefGoogle Scholar
  31. 32.
    Rose GA. Variability of angina, some implications for epidemiology. Br J Prevent Soc Med 1968;22:12–15.Google Scholar
  32. 33.
    Shaper AG, Cook DG, Walker M, MacFarlane PW. Recall of diagnosis by men with ischaemic heart disease. Br Heart J 1984;51:606–11.PubMedCrossRefGoogle Scholar
  33. 34.
    Isles CG, Hole DG, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Paisley and Renfrew survey: comparison with men. Lancet 1992;339:702–6.PubMedCrossRefGoogle Scholar
  34. 35.
    Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonene H, Ruokokoski E, Asmouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10- year results from 37 WHO MONICA project populations. Lancet 1999;353:1547–57.PubMedCrossRefGoogle Scholar
  35. 36.
    Kornitzer M, Rose GA. Who European collaborative trial of multifactorial prevention of coronary heart disease. Prevent Med 1985;14:272–8.CrossRefGoogle Scholar
  36. 37.
    Rose G, Ball K, Catford J, James P, Lambert D, Maryon-Davis S, et al. Coronary Heart Disease Prevention: Plans for Action. Pitman, London 1984.Google Scholar
  37. 38.
    British Cardiac Society. Working group on coronay prevention. Br Heart J 1987;57:187–9.Google Scholar
  38. 39.
    Reduction in incidence of coronary heart disease. Lipid research clinics coronary prevention trial, Results 1. JAMA 1984;251:351–64.CrossRefGoogle Scholar
  39. 40.
    Oliver MF. Might treatment of hypercholesterolaemia increase noncardiac mortality?Lancet 1991;337:1529–31.PubMedCrossRefGoogle Scholar
  40. 41.
    British Cardiac Society. Survey of the potential for the secondary prevention of coronary disease. Aspire Steering Group. Heart 1996;75:334–42.CrossRefGoogle Scholar
  41. 42.
    British Heart Foundation Health Promotion Research Group. Coronary heart disease statistics. London: British Heart Foundation, 1999.Google Scholar
  42. 43.
    Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81:380–6.PubMedGoogle Scholar
  43. 44.
    National Heart Forum. Looking to the future. London: Stationery Office, 1999.Google Scholar
  44. 45.
    Osier W. Meeting of Southern Medical Society, Glasgow 5th October 1911. (Item by W Watson Buchanan). Bull R Coll Physicians Surgeons Glasgow 1999;28:18–21.Google Scholar
  45. 46.
    Pickering GW. High blood pressure. London: J and A Churchill, 1955.Google Scholar
  46. 47.
    Watt GC, Foy CJ, Hart JT. Dietary sodium and blood pressure in young people with and without familial predisposition to high blood pressure. J Clin Hypertens 1986;2:141–7.PubMedGoogle Scholar
  47. 48.
    Hart JT. Hypertension and the prevention of coronary heart disease in general practice. Postgrad Med J 1984;60:34–8.PubMedCrossRefGoogle Scholar
  48. 49.
    Lichtenstein MJ, Shipley MJ, Rose G. Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study. BMJ 1985;291:243–5.PubMedCrossRefGoogle Scholar
  49. 50.
    Medical Research Council. Trial of mild hypertension. Lancet 1985;325:92–5.Google Scholar
  50. 51.
    Collins R, McMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. BMJ 1994;50:272–8.Google Scholar
  51. 52.
    British Cardiac Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):51–29.Google Scholar

Copyright information

© Springer-Verlag London Limited 2000

Authors and Affiliations

  • Ross Lorimer

There are no affiliations available

Personalised recommendations